⚕ GalenOps CRO console
← SITE004 (DEU)

SITE004-0375

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE004 (DEU) (Dr. Tanaka) · consented 2023-05-19
Adverse events
9
Serious AEs
2
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-15 (study day 20); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-03 (study day 38); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-07-06 (study day 41); relationship: N; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-07-07 (study day 42); relationship: N

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-10 (study day 45); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-07-28 (study day 63); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 66); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-05 (study day 71); relationship: not assessed; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-20 (study day 86); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.